

Mirtazapine Disintegrating Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 51106-00022 Date of last issue: 04.04.2023
Date of first issue: 23.01.2015

SECTION 1. IDENTIFICATION

Product name : Mirtazapine Disintegrating Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 1-551-430-6000

Emergency telephone : 1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Acute toxicity (Oral) : Category 4

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Nervous system)

Short-term (acute) aquatic hazard : Category 3

Long-term (chronic) aquatic hazard : Category 3

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373 May cause damage to organs (Nervous system) through

Mirtazapine Disintegrating Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 51106-00022 Date of last issue: 04.04.2023
Date of first issue: 23.01.2015

prolonged or repeated exposure if swallowed.
H412 Harmful to aquatic life with long lasting effects.

Precautionary Statements

:

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	>= 20 -< 25
Citric acid	77-92-9	>= 1 -< 5
Cellulose	9004-34-6	>= 1 -< 5
Magnesium stearate	557-04-0	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

In case of skin contact	:	Get medical attention. In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	:	Harmful if swallowed. Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO _x) Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec-	:	Use personal protective equipment.
-------------------------------	---	------------------------------------

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

- tive equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Store in accordance with the particular national regulations.

- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Mirtazapine Disintegrating Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 51106-00022 Date of last issue: 04.04.2023
Date of first issue: 23.01.2015

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	TWA	25 µg/m ³	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Cellulose	9004-34-6	CMP	10 mg/m ³	AR OEL
		TWA	10 mg/m ³	ACGIH
Magnesium stearate	557-04-0	CMP	10 mg/m ³	AR OEL
	Further information: A4 - Not classifiable as a human carcinogen			
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often!
For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.

SAFETY DATA SHEET



Mirtazapine Disintegrating Formulation



Version 5.1 Revision Date: 30.09.2023 SDS Number: 51106-00022 Date of last issue: 04.04.2023
Date of first issue: 23.01.2015

Hygiene measures : Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity	:	Acute toxicity estimate: 1.588 mg/kg Method: Calculation method
---------------------	---	--

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Acute oral toxicity	:	LD50 (Rat): 320 - 490 mg/kg
---------------------	---	-----------------------------

Citric acid:

Acute oral toxicity	:	LD50 (Mouse): 5.400 mg/kg
---------------------	---	---------------------------

Acute dermal toxicity	:	LD50 (Rat): > 2.000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal
-----------------------	---	--

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

toxicity

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Magnesium stearate:Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materialsAcute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials**Skin corrosion/irritation**

Not classified based on available information.

Components:**Citric acid:**Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation**Magnesium stearate:**Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials**Serious eye damage/eye irritation**

Not classified based on available information.

Components:**Citric acid:**Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405**Magnesium stearate:**Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Mirtazapine Disintegrating Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 51106-00022 Date of last issue: 04.04.2023
Date of first issue: 23.01.2015

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Magnesium stearate:**

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: unscheduled DNA synthesis assay
Test system: mammalian cells
Result: negative

Test Type: sister chromatid exchange assay
Test system: mammalian cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Rat
Cell type: Bone marrow
Application Route: Oral
Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: in vitro micronucleus test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Mouse
Application Route : Oral
Exposure time : 18 month(s)
LOAEL : 200 mg/kg body weight
Result : equivocal
Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years
LOAEL : 20 mg/kg body weight
Result : equivocal
Target Organs : Liver, Thyroid

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

Cellulose:

Species : Rat
 Application Route : Ingestion
 Exposure time : 72 weeks
 Result : negative

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Oral
 Fertility: LOAEL: 15 mg/kg body weight
 Symptoms: Effect on estrous cycle, Increase of early resorptions.
 Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

Effects on fetal development : Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: LOAEL: 100 mg/kg body weight
 Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: NOAEL: 40 mg/kg body weight
 Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

Citric acid:

Effects on fetal development : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

Species: Rat
Application Route: Ingestion
Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

Components:**Citric acid:**

Assessment : May cause respiratory irritation.

STOT-repeated exposure

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Routes of exposure : Ingestion
Target Organs : Nervous system
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Rat
LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Nervous system

Species : Dog
LOAEL : 15 mg/kg
Application Route : Oral

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

Exposure time	:	52 Weeks
Target Organs	:	Nervous system
Symptoms	:	Tremors
Species	:	Dog
LOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	13 Weeks
Target Organs	:	Nervous system, Testis
Symptoms	:	Tremors

Citric acid:

Species	:	Rat
NOAEL	:	4.000 mg/kg
LOAEL	:	8.000 mg/kg
Application Route	:	Ingestion
Exposure time	:	10 Days

Cellulose:

Species	:	Rat
NOAEL	:	>= 9.000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Magnesium stearate:

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Ingestion	:	Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation
-----------	---	--

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 6,92 mg/l Exposure time: 96 h Method: FDA 4.11
------------------	---	---

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 19,5 mg/l
Exposure time: 48 h
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 5,7 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 3,2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 3,6 mg/l
Exposure time: 31 d
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,32 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
- Toxicity to microorganisms : EC50 (Natural microorganism): > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
- NOEC (Natural microorganism): < 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
- Citric acid:**
- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1.535 mg/l
Exposure time: 24 h
- Cellulose:**
- Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials
- Magnesium stearate:**
- Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

Method: Directive 67/548/EEC, Annex V, C.2.
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
 Exposure time: 16 h
 Test substance: Water Accommodated Fraction
 Remarks: Based on data from similar materials

Persistence and degradability**Components:****Citric acid:**

Biodegradability : Result: Readily biodegradable.
 Biodegradation: 97 %
 Exposure time: 28 d
 Method: OECD Test Guideline 301B

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable
 Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)
 Bioconcentration factor (BCF): 334
 Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 2,78

SAFETY DATA SHEET



Mirtazapine Disintegrating Formulation



Version 5.1 Revision Date: 30.09.2023 SDS Number: 51106-00022 Date of last issue: 04.04.2023
Date of first issue: 23.01.2015

Citric acid:

Partition coefficient: n-octanol/water : log Pow: -1,72

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Distribution among environmental compartments : log Koc: 4,48

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Sodium hydrogencarbonate

Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Revision Date	:	30.09.2023
Date format	:	dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
--	---	---

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
AR OEL	:	Argentina. Occupational Exposure Limits
ACGIH / TWA	:	8-hour, time-weighted average
AR OEL / CMP	:	TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transporta-

SAFETY DATA SHEET



Mirtazapine Disintegrating Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51106-00022	Date of first issue: 23.01.2015

tion of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8